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ABSTRACT
BACKGROUND: Although vaccination rates in children exceed 90% in the
United States, adults are vaccinated at far lower rates. In order to address
this issue, additional community immunizers are needed, and pharmacists
are in an ideal position to fill this void.
OBJECTIVES: To explore issues and barriers related to implementation of a
pharmacy-based adult vaccine benefit and develop recommendations supporting a pathway for benefit expansion.
METHODS: A literature review on the current environment surrounding
pharmacy-based adult vaccinations and structured interviews were conducted to inform an expert panel meeting using a modified Delphi process
(pre/post survey). The goal was to develop recommendations on how to
improve access to adult vaccines.
RESULTS: Findings suggest employers play a key role in requesting changes in benefit design to include pharmacy-based vaccinations. However, the
lack of consistent communication between pharmacists and primary care
providers remains a significant barrier.
CONCLUSIONS: Pharmacy-based access to vaccinations improves patient
access and benefits individuals and employers. In order to take advantage
of this opportunity, pharmacists must be viewed within the broader context
of preventative care, including pharmacy-based vaccinations.
J Manag Care Pharm. 2014;20(3):273-82
Copyright © 2014, Academy of Managed Care Pharmacy. All rights reserved.

What is already known about this subject
• Although vaccination rates in children exceed 90% in the United
States, adults are vaccinated at far lower rates.
• To address this issue, additional community immunizers are
needed, and pharmacists are in an ideal position to fill this void.
• A pharmacy-based benefit would improve patient access and
reduce the incidence of vaccine-preventable disease.

What this study adds
• Exploration of issues and barriers related to implementation of a
pharmacy-based adult vaccine benefit.
• Specific recommendations supporting a pathway for health
benefit expansion from a health plan, employer, and pharmacy
perspective.
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Implementation of a Pharmacy-Based Adult Vaccine Benefit:
Recommendations for a Commercial Health Plan Benefit

he rate of adult immunization is suboptimal in the United
States. In contrast with childhood vaccination rates,
adult vaccination rates remain low for most Centers for
Disease Control and Prevention (CDC) Advisory Committee
on Immunization Practice (ACIP)-recommended vaccines.
Although vaccination rates in children typically exceed 90% in
the United States,1 adults continue to be vaccinated at low and
variable rates. For example, data from 2011 show that only 16%
of adults had received a recommended herpes zoster vaccination to prevent shingles, and only 30% of young women aged
19-26 years in the United States had received ≥ 1 dose of the
human papilloma (HPV) vaccination,2 while among adolescent
girls aged 13-17 years, only 53% reported receiving ≥ 1 dose,
and only 35% reported ≥ 3 doses of the HPV vaccine.3
Numerous reports in recent years have called for action to
improve adult vaccination rates. Barriers noted in these studies to improving adult vaccination rates include failure of the
vaccine delivery system to reach target populations,4,5 lack
of public knowledge regarding risks of vaccine-preventable
diseases,6,7 skepticism regarding vaccine safety and effectiveness,6-8 lack of financial/reimbursement systems for providers,4,6,9 lack of administrative systems for identifying appropriate patients in medical records and generating vaccination
reminders,6,10 and the lack of vaccination-related performance
measures and incentives (for payers and providers).11
In 2010, the Second National Immunization Congress was
convened with the goal of addressing future vaccine financing
for the United States, with additional focus on adult immunization infrastructure barriers and access challenges.12 Identifying
community immunizers who can supplement the role of
primary care providers (PCPs) becomes pertinent given that
immunization recommendations will expand over the coming years, while primary care is already reeling under present
service demands and cost containment.13 Currently, more than
170,000 pharmacists in the United States have been trained to
provide immunizations, primarily through the nationally recognized certificate training program provided by the American
Pharmacist Association. Pharmacists follow ACIP guidelines as
recommended by the CDC and other public health entities, as
required by state law. A pharmacy-based immunization benefit
as used throughout this article relates to vaccines being initiated by pharmacists in community pharmacies, and vaccines
would be a covered benefit as it would be in a physician’s office.
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■■ Methods
A literature review to investigate the current environment surrounding pharmacy-based adult vaccinations and structured
interviews with professionals highly knowledgeable about
pharmacy-based adult vaccinations were used to inform an
expert panel meeting using a modified Delphi technique with
a pre/post survey.14 Following the literature review, the structured interviews were conducted to further identify and clarify
the range of barriers and issues associated with developing a
pharmacy-based adult vaccine benefit. This led to a full-day
expert panel meeting composed of individuals with experience and expertise in pharmacy-based adult vaccinations, with
the goal of developing specific recommendations and building
consensus where possible for improving access to adult vaccines through a pharmacy-based immunization benefit. This
research project was approved by the University of Southern
California Health Sciences Campus Institutional Review Board
on November 16, 2012.
Literature Review
A comprehensive literature review was conducted to identify relevant papers in the peer-review literature (MEDLINE
2002-January 2013). In addition, a search of nonindexed
sources including professional association websites such as
America’s Health Insurance Plans, Academy of Managed Care
Pharmacy, American Pharmacists Association, health plan
websites, and nonindexed publications was conducted. Search
terms included “vaccine,” “immunization,” “pharmacy,” “pharmacy benefit,” “health plan,” “managed care,” and “cost-effectiveness.” The search strategy identified more than 25 studies,
articles, and other references available for evaluation. Findings
from the literature review were used to develop the structured
interview guide and to build content for key discussion topics
for the expert panel meeting.
Structured Interviews
Following the literature review, a series of brief (20-30 minutes) structured telephone interviews were conducted with a
convenience sample of 3 opinion leaders knowledgeable about
pharmacy-based immunization benefits. Participants for the
structured interview were selected based on their knowledge
of, or association with, policy regarding adult vaccinations and
274 Journal of Managed Care & Specialty Pharmacy

JMCP

March 2014

Non-Commercial Academic Use Only

However, while the community pharmacy is in an excellent
position to support national adult immunization goals, there
are a limited number of commercial health plans that offer a
pharmacy-based immunization benefit, and even when provided, not all ACIP-recommended adult vaccines are covered
or available at the pharmacy. The objectives of this study were
to explore issues and barriers related to implementation of a
pharmacy-based adult vaccine benefit and develop specific
recommendations supporting a pathway for health benefit
expansion as the standard of care.

pharmacy provision of such. In particular, we identified individuals representing a national pharmacy and medical organization, as well as a local health plan. Of the 3 opinion leaders,
1 was invited to participate in the expert panel meeting. The
structured interview guide was used to address 9 openended questions (see Appendix A, available in online article).
Participation in the structured interview was voluntary, and
the discussion was conducted in a heuristic manner, allowing the interviewers to probe beyond the initial question. The
results from the structured interviews were used to construct
the consensus-generating pre/post meeting survey, which was
used during the expert panel to help facilitate discussion.
Recruitment of the Expert Panel
Members of the expert panel were recruited based on recommendations from participants in the structured interview and
a profile of leadership in the area of adult vaccines and pharmacy-based health care benefits. We targeted individuals based
on their organizational (i.e., health plan, large employers) or
professional (i.e., national pharmacy/medical organizations)
affiliations, as well as publications in the area of adult vaccinations. The 12-member panel was composed of health plan (3)
and pharmacy benefit managers (PBM; 3), medical/pharmacy
directors, employer medical and health benefits directors (3),
chain pharmacy representatives (2), and an immunization policy expert (1). An academic pharmacist immunization expert
was employed as the key opinion leader to provide input and
facilitate discussion.

Modified Delphi Process
The modified Delphi process included 2 rounds of ratings. In
round 1, leading up to the meeting, panelists were asked to
complete a brief premeeting survey to rate statements pertaining to adult vaccinations (see Appendix B, available in online
article). The goal of the survey was to determine baseline viewpoints of each panelist and to identify areas of consensus and
disagreement among the various stakeholders. By doing so,
the subsequent in-person discussion could be more focused.
In round 2, at the close of the meeting, panelists were asked
to complete a postmeeting survey consisting of select opinionbased questions from the premeeting survey to determine
if panelists’ views changed after the meeting. We utilized a
modified Delphi technique as opposed to a traditional Delphi
technique, since responses were not anonymous, and we used
only 2 rounds of rating regardless of consensus.
The pre- and postmeeting surveys were developed based
on findings from the literature review and feedback from the
structured interviews. The survey was composed of 3 different
sections: The first focused on general background information
regarding adult vaccination and vaccination rates; the second
section asked specifically about pharmacy-based adult vaccination; and the third section focused on research/resources
relevant to a pharmacy-based benefit. The survey asked
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Distribution of Select Survey Results
Disagreement
(1-3)
Prea

Post a

Health plan benefit design impacts adult vaccination rates
1
2
Lack of public recognition regarding need for adult vaccinations impacts adult
1
0
vaccination rates
Cost of vaccines for patients impacts adult vaccination rates
2
3
Vaccine shortages impact adult vaccination rates
4
4
Physicians are responsible for helping to improve adult vaccination rates
0
0
Patients are responsible for helping to improve adult vaccination rates
0
1
Health plans are responsible for helping to improve adult vaccination rates
1
0
A pharmacy-based adult vaccination benefit would improve adult
1
0
vaccination rates
A pharmacy-based adult vaccination benefit would result in cost savings for the
1
2
health plan and employer
A pharmacy-based benefit would improve public acceptance of vaccine
1
1
safety/effectiveness
Ease of access for patients is important when/if considering a pharmacy-based
1
1
adult vaccine benefit
Coordinated reporting of vaccines is important when/if considering a
0
0
pharmacy-based adult vaccine benefit
Lack of standard reimbursement process is a significant barrier
2
0
Uncertain cost-effectiveness is a significant barrier
4
1
Safety of vaccines administered by pharmacists is an issue
5
7
a Denotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.

panelists to provide ratings on a 9-point scale (1 = strongly
disagree; 5 = uncertain; 9 = strongly agree), as well as respond
to several open-ended questions. Average ratings between 1
and 3 were considered as indicating disagreement, average
ratings between 4 and 6 as uncertain, and average ratings
between 7 and 9 as indicating agreement. Disagreement or lack
of consensus was defined as occurring when at least 2 panelists rated any scenario as disagree (1-3) and at least 2 panelists
rated the same statement as agree (7-9), regardless of average
rating. The survey included 3 separate sections focusing on (a)
background knowledge on adult vaccinations, (b) perspective
regarding pharmacy-based adult vaccination benefit, and (c)
areas of need pertaining to future studies/research. In addition
to rating each statement, panelists could also add comments to
particular statements.
Expert Panel Meeting
The expert panel meeting was organized into four 90-minute
sessions over the course of the day, with each session having
a distinct focus. The goal for the first session was to have an
open discussion about the current state of pharmacy-based
adult vaccine benefits. Panelists were provided with an overview of findings from the literature review and encouraged to
share initial thoughts based on their experience and understanding of pharmacy-based adult vaccine benefits. Round 2
of the modified Delphi model occurred during the second session. Results from the premeeting survey were used to frame
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Unsure
(5-7)

Agreement
(7-9)

Mean

Pre
2
2

Post
2
1

Pre
9
9

Post
8
11

Pre
7.08
7.25

Post
6.58
7.83

6
2
0
1
0
0

5
4
0
0
3
1

3
6
12
11
11
11

4
4
12
11
9
11

5.75
5.33
8.33
7.92
7.50
7.17

5.25
5.42
8.58
7.67
7.42
7.50

4

4

7

6

6.75

5.83

5

3

6

8

6.00

6.50

1

1

10

10

7.42

7.75

3

0

9

12

7.25

8.33

1
5
4

2
7
4

9
3
3

10
4
1

6.92
5.08
4.75

7.75
5.67
3.25
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TABLE 1

discussions and target areas where there was disagreement or
where consensus was lacking; panelists were asked to elaborate on their responses (see Appendix C, available in online
article). The goal for the second session was to reach initial
consensus on issues where survey results indicated there was
disagreement. The goal of the third session was to share new
information and research regarding pharmacists as vaccinators and issues related to vaccine financing currently and in
the near future. During the third session, our focus was to
inform panelists of information with which they may not have
been familiar. The fourth session focused on producing workgroup consensus and recommendations across 6 broad areas
that were previously identified through the literature review
and structured interviews. The goal of the fourth session was
to drive the discussion toward specific recommendations to
provide a roadmap leading to a pharmacy-based adult immunization benefit design.
■■ Results
Survey
The response rate for the pre- and postmeeting survey was
100% (n = 12), and there were no missing data. Select results
from both the pre- and postmeeting survey are presented in
Table 1. The premeeting survey asked panelists to rate various
statements (1 = strongly disagree; 5 = uncertain; 9 = strongly
agree) and revealed general agreement that health plan benefit
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design and lack of public recognition regarding the importance
of adult vaccinations were important barriers to improving
adult vaccination rates. However, panelists disagreed on the
importance of the cost of vaccines and the impact of vaccine
shortages on adult vaccination rates. When panelists were
asked what they believed were the most significant barriers
to improving adult vaccination rates, payment processing and
lack of coordinated reporting were most frequently identified.
When asked about who was most responsible for improving vaccination rates, they reported physicians, patients, and
health plans, while there was disagreement regarding the
responsibility of government regulators and government payers on improving rates. Although panelists were in general
agreement that pharmacy-based vaccination could improve
vaccination rates and result in cost savings, there was only
moderate agreement that a pharmacy-based benefit would help
improve public acceptance of vaccine safety and effectiveness.
For those considering a pharmacy benefit, ease of access for
patients and coordinated reporting of vaccine administration
were most important. However, there was a lack of consensus
when it came to the safety of vaccinations administered by
pharmacists, due to the lack of pharmacists having access to a
full patient history. When asked about the most useful type of
information in evaluating a pharmacy-based vaccine benefit,
models of best practice and vaccine registries were reported
as most useful. Panelists disagreed regarding the utility of
cost-effectiveness modeling, retrospective claims research,
and patient surveys to evaluate pharmacy-based vaccination
programs.
Responses to the postmeeting survey revealed that few attitudes had changed, possibly because most panelists had strong
preformed opinions regarding adult vaccinations and the role
of pharmacy-based benefits (see Table 1). For instance, postmeeting results indicated that panelists still disagreed about
which factors would impact adult vaccination rates (i.e., vaccine cost and vaccine shortages) and who was most responsible
for improving vaccination rates (i.e., government regulators
and payers). However, postmeeting survey results did indicate
consensus in some areas where panelists previously disagreed.
For instance, premeeting results indicated panelists disagreed
whether standardization of the payment process, uncertain
cost-effectiveness, and safety concerns over pharmacists as vaccinators were barriers to a pharmacy-based benefit. According
to postmeeting results, panelists agreed that uncertain costeffectiveness and the lack of a standardized payment process
were barriers to a pharmacy-based benefit, but not safety of
pharmacist-administered vaccinations. Other areas where
consensus was achieved include the utility of cost-effectiveness
modeling, retrospective claims analysis, and patient surveys,
but all of these were considered only moderately useful.
Overall, results from the literature review, structured interviews, and premeeting survey identified 6 broad areas that

provided direction for the expert panel meeting: benefit design,
billing and payment, regulatory issues, immunization documentation and communication across providers, stakeholders
who are responsible for adult vaccinations, and future research
needs. Findings from the expert panel discussion are summarized as follows.
Expert Panel
This section highlights findings from the expert panel discussion, focusing on 6 key areas related to a pharmacy-based adult
vaccine benefit.
Benefit Design. Panelists agreed that one of the most significant barriers to improving adult vaccination rates is benefit
design in that members are simply not aware of the benefits
available to them, benefits are confusing, and lack of understanding as to where benefits can be accessed. Thus, one of the
first areas that should be addressed prior to implementing any
benefit design change is to develop user-friendly tools to help
members understand their benefits. The panelists believed that
offering free vaccines is an insufficient incentive to increase
vaccination rates and that members may need additional
incentives (e.g., discounts on premiums) in addition to providing user-friendly tools to determine which benefits they have
available and where they can access them. In addition to lack of
awareness among members, the panelists stated that a lack of
public recognition for the need for adult vaccinations is another
important barrier impacting adult vaccination rates.
From an administrative standpoint, panelists reported
that benefit design is strongly affected by third-party brokers
of medical and pharmacy benefits. Brokers often purchase
services in a piecemeal approach, with medical, pharmacy,
and behavioral health benefits purchased separately. Panelists
called for increased consistency specifically in the purchase of
integrated services. It was also noted that purchasing an option
for the integration of data among the various parts of the benefit is frequently overlooked or refused by the purchaser (i.e.,
employers). In this regard, there is a clear need for purchasers
to keep brokers accountable in offering data integration and
for buyers to include these services in the purchasing decision.
The panelists representing employers conveyed that outside of influenza, they were unaware of data suggesting any
worker productivity benefits of increasing the rate of adult
vaccinations or expanding such a benefit. These payers were
not convinced of the cost-benefit of additional adult vaccines,
particularly when balancing the additional cost of increased
vaccination rates using alternative delivery methods such as
pharmacy-based immunization. In this regard, it became clear
that employers require strong value propositions before considering adding benefits or publicizing available/existing benefits.
Billing. Panelists agreed that the lack of coordinated payment
processes between pharmacy and medical benefits and the
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Regulatory/Scope of Practice. Although pharmacists are
authorized to administer vaccines in every state, variations
exist regarding the type of vaccines and age of eligible patients
to which pharmacists can administer vaccines. Large employers with a presence in multiple states specifically mentioned
varying state laws as a barrier in establishing a pharmacybased benefit, as large employers have to manage benefits differently across states. However, there was a lack of consensus
within the panel as to whether or not varying state laws were
in fact a barrier to a pharmacy-based benefit.
Among those who agreed state laws were a barrier to a
pharmacy benefit, panelists mentioned that state medical
association support would likely be required to expand state
practice laws. In particular, state medical associations with
the assistance of state/county public health associations and
physician groups could help to support expanded state regulations authorizing pharmacists as full vaccine providers. The
Patient Centered Primary Care Collaborative was suggested as
a national organization that could fashion a policy statement
to be utilized at the state level to support expanded practice
authority for pharmacist vaccine administration.
Physician panelists reported that physicians are generally
comfortable with pharmacists as vaccine providers, although
the ability of pharmacists to properly screen patients for a
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administration of those benefits by the PBM and health plan
are a significant barrier. Moreover, payment processes were
also seen as one of the most important factors when considering the issues regarding offering a pharmacy-based vaccine
benefit. A common issue mentioned by health plan and PBM
panelists was duplicative billing. The case was made that physicians may be denied payment for a vaccine claim where the
health plan had already reimbursed a pharmacy for administering the vaccine. Panelists indicated that coordination of
services reporting among providers and the health plan/PBM
is a priority. Coordinated reporting of vaccine administration
beyond billing will be discussed separately.
Options for pharmacy billing of vaccination were also
discussed, and the consensus opinion was that it would be
most efficient to have pharmacies use the current National
Council for Prescription Drug Programs (NCPDP) standard.
Pharmacies already include the capability to bill for the product (i.e., vaccine) and administration of the vaccine separately,
as opposed to introducing an alternative billing system based
on the medical claim process. Rather than compel pharmacies to submit claims using the medical benefit billing system,
the panel agreed that health plans and PBMs should accept
billing for pharmacy administration of vaccines through the
current NCPDP billing system. Additionally, no consensus
was reached on how to approach restricted network capitation
models where medical groups are responsible for providing all
nondrug services, including vaccinations.

wide range of vaccinations with limited patient history did
raise some concern. Recent efforts with the H1N1 pandemic
program were cited as a model of how loosening state law
during a pandemic for pharmacists can be very effective at
rapidly increasing vaccination rates. For example, pharmacistprovided immunizations expanded considerably following
the 2009 H1N1 influenza pandemic and seasonal influenza
outbreak. This public health crisis highlighted the role that
pharmacists can play and positioned the profession to continue
advancing immunization opportunities that improve public
health by reaching patient populations in need or at risk.15,16
There was consensus that adult vaccination rates would
also improve if patients had a pharmacy-based immunization
benefit. Furthermore, health plan panelists indicated that physicians often carry a limited number of vaccines and that the
provision of vaccinations may be a poor utilization of physician
time. In fact, a recent study conducted by the American Medical
Association found that only 20%-30% of internists and family
physicians stocked all CDC-recommended vaccines; 80% were
not planning on increasing their offerings; and 2% were planning to stop carrying vaccines altogether.17 There was continuing disagreement among panel members over provider status
for pharmacists. Provider status for pharmacists under the
Social Security Act is generally thought to be necessary to allow
pharmacists to be consistently paid by Medicaid and private
insurers. When asked to elaborate, those expressing hesitancy
over pharmacists as vaccine providers indicated that without
appropriate information exchange (i.e., communication back
to the PCP), physicians remain reluctant to recognize other
providers as vaccinators. It appears that consensus is unlikely
to be achieved regarding the recognition of pharmacists as vaccine providers until information exchange is more effectively
coordinated between pharmacists and PCPs. It is important to
note that the lack of information exchange encompasses not
only pharmacists but others such as physician subspecialists,
public health agencies, and hospitals.
One suggestion for establishing a closer link between pharmacists and PCPs was to include pharmacists into the primary
care medical home model.18 Doing so could ensure that physicians are aware of any vaccinations that patients receive.
Immunization Documentation and Communication. There
was broad agreement that lack of coordinated care between
pharmacies and PCPs was a significant barrier related to
pharmacy-based adult vaccinations. Current reporting practices include the pharmacy sending a fax or letter to the physician’s office. However, this has not proven to be effective and,
in many cases, is viewed as additional administrative work to
get the information into the patient’s record. Given the general absence of data sharing and reporting mechanisms, some
health plans have retained vaccination benefits at the physician
level rather than proactively building systems that coordinate
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Responsibility for Vaccination Rates. Panelists identified
physicians as the most responsible for the improvement in
adult vaccination rates, followed by patients, insurance companies, pharmacists, and employers. In addition, panelists
focused on employers as having the potential to play a pivotal
role in the improvement of adult vaccination rates. It was
suggested that employers can specifically request that their
health plans and brokers include a pharmacy-based vaccination benefit in their benefit design. For smaller employers,
278 Journal of Managed Care & Specialty Pharmacy
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the reporting of services among different providers. Despite
the fact that panelists agree on the value of pharmacy as a high
volume access point, the lack of data exchange between pharmacies and PCPs remains a significant barrier.
In order to address this issue, panelists suggested utilizing
the electronic medical record (EMR) for 2-way communication
between pharmacists and PCPs. One area where a collaborative approach was suggested is in the instance of a vaccination
series, such as that for HPV or hepatitis B. It was suggested
that the PCP could administer the first vaccination, with subsequent vaccinations taking place at a pharmacy. This could
help alleviate the concern regarding the appropriateness of vaccination based on a patient’s full medical history. Once the PCP
transitions the responsibility for completing a vaccine series to
the pharmacy/pharmacist, the issue of information exchange
could also be addressed while also utilizing the increased
accessibility of community pharmacists.
Panelists also suggested the inclusion of pharmacists in
other electronic reporting solutions, such as immunization
registries or state health information exchanges, as a way to
increase coordinated care between pharmacists and PCPs. For
example, providing pharmacists access to highly populated
registries would allow pharmacists to actively seek, contribute, and view immunization records so that all providers are
informed. Physicians currently can e-prescribe medications
to pharmacies, and pharmacists can send refill requests back
through the same system. Panelists suggested modifications to
the current system by allowing pharmacists to update a physician’s medical record using only their pharmacy information
management system. Lastly, panelists reported that the expectation under new state health information exchanges (HIEs)
is that every provider will have access to a real-time patient
record, which could be used as a central vaccination record.
However, in order for this to work, there is a need to have pharmacists recognized as providers within the HIEs. Establishing
pharmacists as providers through state HIEs, coupled with
access to patient records, may provide a reporting mechanism
to PCPs and a basis for pharmacists to administer all vaccines.
As with any reporting system, it is essential that providers
check the system prior to providing services, something the
panel indicated that neither physicians nor pharmacists currently do well, since they are better at data entry than retrieval.

this may mean working closely with brokers to specify benefit
design decisions to include a pharmacy-provided benefit, even
if vaccinations remain part of the medical benefit. In addition,
member awareness of available health benefits was also viewed
as the responsibility of the employer, given that employers
are most invested in the health of their employees. Employers
are encouraged to work with the health plan/PBM to provide
employees with easy-to-understand descriptions of their health
benefits and how to access them.
There was also consensus that community pharmacies can
play a more substantial role in increasing adult vaccination
rates. Health plan representatives reported that one of their
primary concerns was whether or not community pharmacies
could provide consistent services across locations and be able
to deliver vaccinations during all business hours. However,
professional pharmacy associations report that pharmacists
have already started addressing this issue, with more than
60,000 community pharmacies in the United States reportedly
offering convenient, accessible, and extended hours of operation for vaccine administration.19,20
One suggestion was that pharmacists have an opportunity
to make a larger contribution to help improve public health. If
vaccination benefits were to be expanded to include pharmacy
administration, the expectation was that pharmacists should
leverage patient encounters to not only provide vaccines, but
also take the opportunity to provide other preventive health
services as recommended by the U.S. Preventative Health
Services Task Force. There was concern that focused provision
of vaccination alone may squander an opportunity to provide
additional preventive health services such as counseling regarding additional ACIP-recommended vaccines, monitoring health
status, and performing additional health screenings. Panelists
recognized the potential value of the pharmacy-based patient
encounter as an opportunity to provide other preventive health
measures to complement the current physician-based system.
Health plan and PBM responsibilities regarding vaccinations
were also addressed by the panel. The panel recognized that
health plans and PBMs often operate independently and under
different medical and pharmacy benefit silos. Regardless, the
panel believed these entities were responsible for and best
positioned to provide data integration across providers. In
addition, health plans and PBMs should work with employers
to improve the patient experience accessing and using their
health benefits. While vaccine manufacturers were seen as just
moderately responsible for improving adult vaccination rates,
the panel strongly suggested that manufactures were responsible for the perception of vaccine efficacy, safety, and value by
providing appropriate messaging with high-quality evidence.
Consensus was not achieved regarding the role of government regulators and government payers (e.g., Centers for
Medicare & Medicaid Services) and their responsibility in
improving adult vaccination rates. Among those who felt the
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Future Research. Employers called for additional research
demonstrating the value of adult vaccines beyond seasonal flu.
It was apparent that employers remained skeptical regarding
the near-term value associated with increasing adult vaccination rates by offering adult vaccines through pharmacydelivered benefits or other providers. Employers are interested
in additional information to help them determine the value of
increasing adult vaccination rates and offering the additional
benefit of pharmacy-based vaccinations.
Outcomes of particular interest to employers included
employee productivity, absenteeism, and the overall cost-effectiveness of adult vaccines. Health plan panelists were interested
in reduction of adverse events and the elimination of duplicative billing charges. Evidence of value needs to be specific for
the various adult vaccines, as panelists generally agreed that
influenza, tetanus diphtheria-pertussis (Tdap), and pneumococcal vaccines likely provide near-term value, but they were
much less certain of the value provided by other vaccines such
as herpes zoster and HPV.
Panelists perceived that employers had poor understanding
of the low rate of adult vaccinations within their populations
and where vaccinations were currently being administered. In
this regard, providing data on vaccination and utilization rates
may help highlight the importance of this issue and also help
employers understand the importance of improving adult vaccination rates.
Health plan panelists also mentioned that Healthcare
Effectiveness Data and Information Set (HEDIS) scores, Centers
for Medicare & Medicaid Services stars ratings, and accountable care organizations associated targets for adult vaccination
rates provide an incentive to increase rates, potentially through
expanded access. Focusing on adult vaccinations as part of
quality measures would help all stakeholders recognize the
importance of adult vaccines.
Panelists identified that the 2 most important sources of
information when evaluating the impact of a pharmacy-based
benefit were peer-review journals and ACIP recommendations.
In addition, panelists indicated the organizations best suited
to conduct future research would be academic institutions or
independent research organizations.
Workgroup Recommendations
During the final session of the expert panel meeting, panelists
were asked to provide specific actionable recommendations
across the 6 topics discussed throughout the expert panel
meeting. Specific workgroup recommendations outlining a
roadmap to a pharmacy-based adult immunization benefit are
presented in Table 2.
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government had a limited role, it was suggested that government responsibilities for adult vaccinations were limited to
public health agency recommendations.

■■ Discussion
The Patient Protection and Affordable Care Act (PPACA),
signed into law in 2010, requires government and commercial
plans to cover essential benefits, which include wellness and
clinical preventive services, including vaccines recommended
by the CDC’s ACIP. These services must be offered without
cost sharing by nongrandfathered health plans, and there are
financial incentives for states to increase their coverage of preventive services.
Pharmacists and community pharmacy locations are in
an ideal position to meet this growing need for preventative
services. Pharmacist-provided immunizations are clinically
sound, cost effective, readily accessible, and have demonstrated
the ability to support our nation’s public health goals. Although
there are varying state regulations regarding pharmacists as
vaccine administrators, all 50 states currently allow pharmacists to administer vaccines.17,21,22 Duncan et al. (2012) created
a cost-benefit model around influenza vaccination programs
and reported that an influenza immunization program is cost
beneficial to employers when more than 37% of individuals
receive vaccine in nontraditional settings such as pharmacies,
with an estimated net saving of $6 per vaccine.23 In addition,
Prosser et al. (2008) reported that the cost (2004 U.S. dollars)
of vaccination was lower in mass vaccination clinics ($17.04)
and pharmacy ($11.57) settings than in scheduled doctor’s
office visits ($28.67).24
The purpose of this project was to identify issues and barriers related to a pharmacy-based adult vaccine benefit and
develop recommendations to support a pathway for benefit
design change. Based on our findings, the barriers associated
with overcoming a pharmacy-based benefit revolve around
3 distinct areas: increased engagement by employers, lack of
coordinated reporting, and insufficient recognition of the community pharmacy and pharmacist as vaccine providers.
First, it is clear that employers must play a more proactive role in incorporating explicit changes in benefit design.
However, in order to consider any benefit changes, they
require sound value propositions to guide directed use of
limited organizational resources. As such, pharmacy vaccination benefit would have to show relatively greater near-term
value in comparison to other health management initiatives to
prompt sufficient employer focus to enhance vaccine benefit
design. Although employers are not necessarily calling for costeffectiveness data given the relatively low cost of vaccines, they
would benefit from more substantial evidence demonstrating
the impact of adult vaccines on health care costs and workforce
productivity and absenteeism.
Second, from an administrative standpoint, the ability to
ensure consistent reporting and data exchange between community pharmacists and PCPs is of significant importance.
Due to issues such as the potential for duplicative billing
and lack of data exchange between pharmacies and PCPs,
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TABLE 2

Workgroup Recommendations

Recommendations
• Increase member awareness of what benefits are covered and how to access them with user-friendly applications
• Health care brokers and purchasers (i.e., employers) need to offer and purchase or develop data integration services across medical and
pharmacy benefits
• Provide evidence to support value propositions for employers demonstrating near-term value of increasing access to a broad range of
Benefit design
adult vaccines
• Create pharmacy-based vaccine benefits that use one of the following models:
o Include vaccines and vaccine administration on a PBM’s list of covered products
o Bring pharmacies into a health plan’s medical network to allow in-network delivery of the vaccine as a medical benefit
• All vaccine providers need to have easily accessible data regarding services provided by other health care providers to avoid duplicate
billing issues
Billing
• Utilize current pharmacy information management systems for processing adult vaccination claims and have the health plan or PBM
attach the claim to the appropriate benefit
• Develop a nationally endorsed policy statement to be used by state medical associations and state/county health departments supporting pharmacists as vaccine providers
Regulatory
• Conduct a “proof of concept” project in select states generating real-world data demonstrating successful information exchange between
pharmacies and health plans
Immunization
• Provide a method for real-time reporting of vaccines administered among all types of providers and the health plan/PBM
documentation
• Develop protocols for the administration of a vaccination series, which includes coordination among physicians and pharmacists using
and
the EMR where available
communication • Include pharmacists as providers within state HIEs
• Employers need to be more proactive in promoting member awareness of health care benefits, including the value of vaccines and
where to access them
Responsibility
• Ensure that community pharmacies have trained pharmacists and protocols to deliver vaccinations consistently across all facilities and
for vaccination
during all business hours
rates
• Pharmacists should use the vaccine encounter to provide more comprehensive preventive health services
• Manufacturers need to provide additional evidence and effective messaging regarding the efficacy, safety, and value of vaccines to help
improve public and payer perception of adult vaccinations
• Generate additional evidence on the cost benefit of adult vaccinations, focusing on productivity and absenteeism
• Include adult vaccination rates for ACIP-recommended vaccines as quality measures within the National Committee for Quality
Future research
Assurance HEDIS quality reporting dataset
• Partner with independent academic institutions or third-party research organizations to conduct additional studies
ACIP = Advisory Committee on Immunization Practice; EMR = electronic medical record; HEDIS =Healthcare Effectiveness Data and Information Set; HIE = health
information exchange; PBM = pharmacy benefit manager.

competition for patients, and potential revenue loss, there is
reluctance among physicians and health plans to recognize
pharmacists as vaccine providers. However, this does not call
for an entirely new billing system; instead, the preference is to
leverage the NCPDP pharmacy claims transmission standard
that is already in place. Furthermore, the timing of a pharmacy
benefit is ideal, given the PPACA and state HIEs that are being
established, which also have the potential to address concerns
around information exchange. The millions of newly insured
individuals, along with those now entitled to no-cost vaccines,
provide justification to expand the pool of available sources
and providers for adult vaccinations. Pharmacists are poised to
fill that need, and technology to enhance immunization documentation communication is improving.
Third, despite the fact that physicians are generally accepting of pharmacists as vaccine providers, pharmacists have an
opportunity and obligation to serve a broader role. If pharmacists are to be recognized as providers, they must take
advantage of the patient encounter and provide other preventive health care measures, such as medication adherence. To
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ensure that pharmacists have the ability to do so, endorsement
from external groups such as medical professional associations
and state and local/county public health organizations would
help pharmacists be recognized as providers from a preventive
health perspective, not only of vaccinations but of helping to
establish their role as important members of the health care
team. Nationally, establishing pharmacists as providers under
the Social Security Act will enable health plans and other providers to appropriately recognize pharmacists for participation
in billing and data exchange.
Lastly, despite PPACA legislation and first-dollar coverage
for adult vaccinations, utilization rates remain low.25 There
is a compelling need for enhanced awareness of the value of
adult vaccinations. All stakeholders in the health care delivery
system can advocate for improved immunization rates by promoting available vaccination sources, including pharmacies.
Additionally, employers can enhance communication efforts
regarding adult preventive care services, including vaccines,
with consideration for financial or other incentives to improve
participation rates.
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■■ Conclusions
Consideration for a future state of pharmacy-based adult vaccinations comes at no better time, given the cultural shift taking
place from an acute care model of health care towards a more
preventive approach. As part of a team-based care delivery
model that extends beyond the physical walls of the PCP office,
community pharmacists are ideally trained and positioned to
fill that role. Pharmacy-based access to vaccinations improves
patient access and can benefit individuals and employers
through reduction of the incidence of vaccine-preventable disease. In order to take advantage of this opportunity, pharmacists as providers must be viewed within the broader context
of preventative health care, which includes pharmacy-based
adult vaccinations.
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Limitations
There are several limitations to be noted. First, due to the
scope of the project, a convenience sample of 12 participants
were included in the expert panel, and workgroup recommendations may not be representative of other organizations
or states. For example, we only included employer representatives from large corporations, and panelists clearly indicated
that benefit design decisions are likely to vary based on size of
the employer, since large employers may have more flexibility
in benefit design decisions. Second, our literature review was
comprehensive in nature but may not have included all of the
relevant topics to a pharmacy-based benefit. As a result, our
study focused on 6 broad topics, but other factors are likely to
be important when considering the merits of pharmacy-based
vaccination. Panelists clearly indicated vaccines were viewed
differently in terms of their efficacy, cost-effectiveness, and
safety, making it difficult to generalize our findings across all
adult vaccinations.
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Structured Interview Guide

Adult Immunization Background
1.

Tell me about your adult vaccine benefit [HEALTH PLAN RESPONDENTS]
a.
What adult vaccines are covered and under what type of benefit? Any restrictions on particular adult vaccines?
i.
Flu, pneumovax, H Zoster, Td, Tdap, Hep A, Hep B, MMR, meningitis, others
b. Are your adult vaccines covered under a pharmacy benefit or via alternate benefit arrangements, or only under a medical benefit?
What adult vaccines are you aware of that are covered by health insurance? [NON-HEALTH PLAN RESPONDENTS]

2.

What do you believe are the most important challenges in the area of adult immunizations?
a.
What are your goals for adult immunization?
b. Are you satisfied with (your) uptake and completion rates for adult vaccinations?
c.
Have you implemented (are you familiar with) any strategies to try and improve vaccination rates in your adult population?
i.
Were (do you believe) these improvement strategies (are) successful? Why or why not?
d. Are there particular vaccines that are more difficult than others to increase immunization rates? (i.e., flu, shingles, hepatitis)?
e.
How could the benefit design affect (your) adult immunization goals?

Pharmacy-Based Adult Vaccines & Barriers
3.

Have you considered (or implemented) a pharmacy-based adult vaccine benefit, or have you discussed this with your health plan?
[HEALTH PLAN RESPONDENTS]
a.
Why or why not, what is (or would be) the motivation?
b. What are (were) the barriers (or perceived barriers)?
c.
If yes – what were the barriers you had to overcome?
i.
Are there ongoing challenges?
ii. If your health plan already offers a pharmacy-based immunization benefit, how effective has it been in terms of uptake/completion rates,
cost savings, etc?
d. If no, what would increase your interest in (developing) a pharmacy-based vaccination benefit?
i.
What do you believe has to take place in order to provide pharmacy-based immunization benefits? (In your plan or health plans in general)

4.

What do you believe are the most significant barriers related to implementing a pharmacy-based adult immunizations benefit?
[1 = insignificant, 5 = neutral, 9 = significant]
a.
Administrative/reimbursement/network logistics
b. Cost-benefit ratio (i.e., increased cost due to more vaccine providers and more people getting vaccinated)
c.
Actuarial–PMPM cost estimate
d. No unmet need for adult vaccination/no demand
e.
Offers no competitive advantage
f.
Varying state laws on pharmacy regulations (i.e., licensing requirements)
g.
Inconsistent availability within pharmacy network
h. Documentation of vaccination/record keeping/quality measurement
i.
Abrasion of the medical network
j.
Anything else? [ADDITIONAL EXAMPLES BELOW]
i.
Fragmentation of immunization delivery, lack of reporting to the insurer and PCP, over-vaccination due to different levels of insurance
verification (real-time vs. retrospective), skill level of pharmacist, capitated vs. PPO/FFS, Restricted Networks (under ACA).

5.

Have you addressed any of the barriers identified above?
a.
What approach(es) did you take?
b. Were they resolved, unresolved?
c.
What do you believe will have to change to overcome these hurdle(s)?

6.

How important to you are (were) the following considerations in implementing a pharmacy-based adult immunization benefit?
[1 = not important, 5 = neutral, 9 = very important] - OPTIONAL
a.
Ease of access for patients?
b. Member satisfaction
c.
Lack of availability of (all) vaccines routinely from medical providers?
d. Cost? (medical vs. pharmacy)
e.
Cost effectiveness vs. cost benefit
i.
What specific data would be useful?
ii. What are the most important measures?
iii. What inputs and outputs would you want to see?
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f.
g.
h.
i.
j.

Structured Interview Guide (continued)

Reimbursement
Logistics of reimbursement through the pharmacy payment systems
PBM vs. medical benefit
Physician perception of a pharmacy-based immunization benefit
Other factors?

Future Studies/Resources
7.

What kind of data/studies would be most useful to your health plan when (if) considering an adult vaccine pharmacy-benefit?
[HEALTH PLAN RESPONDENTS]
What kind of data/studies do you believe would be most useful for health plans considering an adult vaccine pharmacy-benefit?
[NON-HEALTH PLAN RESPONDENTS]
a.
Who would be the most appropriate organization to produce such data, inappropriate?
b. What would you consider to be important or convincing results?
i.
Specifically, in what areas would you need to see changes?
c.
Are you aware of any data supporting the value of pharmacy-based programs? If so, what was your impression of that data?

8.

Where do you go for tools and advice regarding a pharmacy-based adult vaccination benefit?
a.
What guidelines or professional organizations do you most refer to when considering benefit design change in the area of immunization?

9.

Would you want a credentialed network of pharmacists who provide your vaccinations? [HEALTH PLAN RESPONDENTS]
a.
If so, what would you want to know about them? (e.g., training, DEA/DOJ/CMS background, license in good standing, etc.)

Non-Commercial Academic Use Only
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ACA = Affordable Care Act; CMS = Centers for Medicare & Medicaid Services; DEA = Drug Enforcement Administration; DOJ = Department of Justice; FFS = fee-for-service;
PBM = pharmacy benefit manager; PCP = primary care provider; PMPM = per member per month; PPO = preferred provider organization.
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Premeeting Survey

Section I: Background
1.

How strongly do you agree or disagree that the following factors impact adult vaccination rates?
1 = Strongly disagree, 5 = Neutral, 9 = Strongly agree
a.
Health plan benefit design strongly influences adult vaccination rates (i.e., uptake/completion)
b. Scope of practice issues limiting the availability of vaccinations at different locations (i.e., physician office, clinic, pharmacies)
c.
Lack of public recognition of the need for adult vaccination
d. Public perception that vaccine risk does not outweigh benefits
e.
Cost of vaccines (for patients)
f.
Vaccine shortages
g.
Other, please describe: __________

2.

How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?
1 = No responsibility, 5 = Neutral, 9 = Very high responsibility
a.
Patients
b. Physicians
c.
Pharmacists
d. Employers
e.
Insurance companies/health plans/PBMs
f.
Vaccine manufacturers/suppliers
g.
Centers for Disease Control (CDC)/Advisory Committee on Immunization Practices (ACIP)
h. Government regulators
i.
Government payers (e.g., Centers for Medicare & Medicaid Services)
j.
Public health agencies (state, county)
k. Professional societies, if so which ones: ________________
l.
Other, please describe: __________

3.

What do you believe is the most significant barrier/challenge to improving adult vaccination rates?

Section II: Pharmacy-based adult vaccination benefit
4.

Does your organization currently offer a pharmacy-based adult vaccine benefit? [HEALTH PLAN PANELISTS]
Are you directly involved with any adult-based vaccination programs? [NON-HEALTH PLAN PANELISTS]
a.
Yes, if so please describe and for how long?
b. No, if not what would increase your interest?

5.

How strongly do you agree/disagree that pharmacy-based adult vaccination benefit availability would help improve the following:
1 = Strongly disagree, 5 = Neutral, 9 = Strongly agree
a.
Adult vaccination rates (i.e., uptake/completion rates)
b. Cost savings (for the health insurer and/or employer)
c.
Public acceptance of vaccine safety and effectiveness

6.

How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?
1 = Strongly disagree, 5 = Neutral, 9 = Strongly agree
a.
Mechanisms to process reimbursements between the pharmacy and health plan or PBM
b. Coordination of reporting of vaccination to primary care providers
c.
Uncertain cost-effectiveness
d. Increased net cost to payer (i.e., increased number of claims for vaccinations)
e.
Varying state laws on pharmacy regulations (i.e., pharmacy practice acts)
f.
Complexity of establishing and credentialing a pharmacy network
g.
Recognition of the pharmacist as a vaccine provider
h. Perception by physicians that pharmacists are taking their revenue/patients
i.
Concern that pharmacists do not obtain adequate patient history to safely administer all adult vaccines
j.
Other, please describe: _________

7.

How important to your decision making are the following factors when considering a pharmacy-based adult vaccine benefit?
1 = Unimportant, 5 = Neutral, 9 = Very important
a.
Ease of access to vaccinations for my members/employees
b. Member/employee satisfaction or loyalty to the health plan/company
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c.
d.
e.
f.
8.

Premeeting Survey (continued)

Availability of a wide range of adult vaccines
Reimbursement processes
Coordinated and consistent reporting of vaccines administered
Other, please describe: _________

What do you believe are the two (2) most significant challenges (to your health plan or to other stakeholders) in establishing a pharmacy-based
adult vaccination benefit?

Section III: Future studies/resources
9.

Non-Commercial Academic Use Only
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What kind of data/study types do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?
1 = Not at all useful, 5 = Neutral, 9 = Very useful
a.
Cost-effectiveness modeling
b. Prospective studies
c.
Retrospective administrative claims analyses
d. Models of best practices
e.
Registry data
f.
Patient surveys
g.
Provider surveys
h. Other, please describe ______________

10. What are the most useful/important sources of information when evaluating a pharmacy-based adult vaccine benefit?
1 = Not useful/unimportant, 5 = Neutral, 9 = Very useful/important
a.
Morbidity and Mortality Weekly Report (MMWR)
b. ACIP recommendations
c.
Peer-reviewed journal articles
d. Professional association guidelines
e.
Professional conferences/meetings
f.
Newsletters
g.
Internet, please indicate websites: _________
h. Discussion with colleagues
i.
Other, please describe: __________
11. What public and/or private organizations are best suited or the most credible to conduct studies or disseminate information about
pharmacy-based adult vaccination benefits?
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Supplemental Data

How strongly do you agree or disagree that the following factors impact adult vaccination rates (i.e., uptake/completion)?
Disagreement (1-3)

Unsure (5-7)

Agreement (7-9)

Post a
Pre
Post
Pre
Prea
1
2
2
2
9
Health plan benefit design
Scope of practice issues
1
0
2
2
9
Lack of public recognition
1
0
2
1
9
Public perception that vaccine risk > benefits
0
1
5
3
7
Cost of vaccines for patients
2
3
6
5
3
Vaccine shortages
4
4
2
4
6
How much responsibility do the following stakeholders have in helping to improve adult vaccination rates?
Disagreement (1-3)

Unsure (5-7)

Post
8
10
11
8
4
4

Mean
Pre
7.08
7.08
7.25
6.75
5.75
5.33

Agreement (7-9)

Post
6.58
7.42
7.83
6.50
5.25
5.42
Mean

Post a
Pre
Post
Pre
Post
Pre
Pre a
Patients
0
1
1
0
11
11
7.92
Physicians
0
0
0
0
12
12
8.33
Pharmacists
1
0
2
4
9
8
7.00
Employers
0
0
4
3
8
9
7.08
Insurance companies/health plans/PBMs
1
0
0
3
11
9
7.50
Vaccine manufacturers/suppliers
0
1
4
6
8
5
6.75
CDC/ACIP
1
1
2
3
9
8
7.17
Government regulators
2
3
5
3
5
6
5.50
2
2
0
3
10
7
6.58
Government payers (e.g. CMS)
Public health agencies (state, county)
1
1
1
2
10
7
7.08
Professional societies
1
1
5
5
6
6
6.33
How strongly do you agree/disagree the availability of a pharmacy-based adult vaccination benefit would help improve the following:
Disagreement (1-3)
Pre a

Unsure (5-7)

Agreement (7-9)

Post a

Pre
Post
Pre
Post
Adult vaccination rates
1
0
0
1
11
11
Cost savings for the health plan and/or employer
1
2
4
4
7
6
Public acceptance of vaccine safety/effectiveness
1
1
5
3
6
8
How strongly do you agree/disagree that the following are barriers/challenges related to a pharmacy-based adult vaccine benefit?
Disagreement (1-3)

Unsure (5-7)

Disagreement (1-3)
Pre a

Post a

1
1
1
1
0

1
1
1
0
0

Ease of access to vaccinations for members/employees
Member/employee satisfaction
Availability of a wide range of adult vaccines
Reimbursement processes
Coordinated and consistent reporting
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Unsure (5-7)
Pre
1
4
6
3
3
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Post
1
4
7
0
0

www.amcp.org

Mean
Pre
7.17
6.75
6.00

Agreement (7-9)

Post a
Pre
Post
Pre
Post
Pre a
Lack of standardized reimbursement process
2
0
1
2
9
10
Coordinated reporting of vaccination to PCP
1
2
3
0
8
10
Uncertain cost-effectiveness
4
1
5
7
3
4
Increased net cost to payer (i.e., increase in claims)
4
3
7
7
1
2
2
2
6
3
4
7
Varying state laws on pharmacy regulations
Complexity of establishing a pharmacy network
2
5
8
5
2
2
Recognition of the pharmacist as a vaccine provider
2
3
6
5
4
4
Perception that pharmacists are taking revenue
4
3
4
7
4
2
Pharmacists ability to safely administer vaccines
5
7
4
4
3
1
How important to your decision making are the following factors when (if) considering a pharmacy-based adult vaccine benefit?
Post
10
7
4
12
12

Post
7.50
5.83
6.50
Mean

Pre
6.92
6.75
5.08
4.33
6.08
5.08
5.75
5.08
4.75

Agreement (7-9)
Pre
10
7
5
8
9

Post
7.67
8.58
7.25
7.17
7.42
5.92
7.08
5.50
6.00
6.92
6.25

Post
7.75
7.08
5.67
5.00
6.17
4.33
5.67
4.92
3.25
Mean

Pre
7.42
6.58
6.17
6.83
7.25

Post
7.75
6.58
6.00
7.67
8.33
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Implementation of a Pharmacy-Based Adult Vaccine Benefit: Recommendations for a Commercial Health Plan Benefit

Supplemental Data (continued)

What kind of data/study TYPES do you believe are most useful when evaluating a pharmacy-based adult vaccination benefit?
Disagreement (1-3)
Prea

Unsure (5-7)

Agreement (7-9)

Post a

Pre
Post
Pre
Post
Cost-effectiveness modeling
4
1
3
0
5
11
Prospective studies
1
0
4
2
7
10
Retrospective administrative claims analyses
2
1
4
2
6
9
Models of best practice
0
1
5
1
7
10
Registry data
0
0
4
3
8
9
Patient surveys
2
0
6
6
4
6
Provider surveys
1
0
8
4
3
8
What are the most useful/important SOURCES of information when evaluating a pharmacy-based adult vaccine benefit?
Disagreement (1-3)
Pre a

Unsure (5-7)

Post a

Agreement (7-9)

Mean
Pre
5.33
6.42
6.00
7.00
6.83
5.92
5.92

Post
6.58
7.33
6.50
7.42
7.25
6.67
6.08
Mean

Pre
Post
Pre
Post
Pre
Morbidity and Mortality Weekly Report (MMWR)
2
0
4
4
6
8
6.00
ACIP recommendations
0
0
2
3
10
9
7.67
Peer-reviewed journal articles
0
0
5
1
7
11
6.92
Professional association guidelines
0
1
8
3
4
8
5.92
Professional conference/meetings
3
1
6
4
3
7
5.25
Newsletters
4
3
5
6
3
3
4.50
Discussion with colleagues
3
1
6
5
3
6
5.33
Internet
2
3
8
5
2
4
4.83
a Denotes number of panelists who were in disagreement, unsure, or agreement with respective survey questions.
ACIP = Advisory Committee on Immunization Practice; CDC = Centers for Disease Control and Prevention; CMS = Centers for Medicare & Medicaid Services;
PBM = pharmacy benefit manager; PCP = primary care provider.
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Post
6.92
7.50
7.92
6.58
6.17
5.00
6.00
5.17
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